Elsevier

Life Sciences

Volume 56, Issue 25, 12 May 1995, Pages 2209-2222
Life Sciences

Minireview
The role of 5-HT2A receptors in antipsychotic activity

https://doi.org/10.1016/0024-3205(95)00210-WGet rights and content

Abstract

The correlation between the clinical activity of antipsychotic agents and their affinity for the D2 dopamine receptor has been the mainstay of the hypothesis that schizophrenia is due to excessive dopaminergic function. More recently, the unique clinical profile of the atypical antipsychotic clozapine has been proposed to involve actions on additional receptor systems. In particular, the high affinity of clozapine for the 5HT2A receptor subtype has been suggested to contribute to its reduced side-effect liability, greater efficacy and its activity in therapy-resistant schizophrenia. We have used the highly selective 5-HT2A antagonist MDL 100,907 to explore the contribution of 5-HT2A receptor blockade to antipsychotic activity. Biochemical, electrophysiological and behavioral studies reveal that selective 5HT2A receptor antagonists have the preclinical profile of an atypical antipsychotic. The limited clinical evidence available also suggests that compounds producing 5-HT2A receptor blockade are effective, in particular, against the negative symptoms of schizophrenia.

References (115)

  • P.A.A. Humphrey et al.

    Trends. Pharmacol. Sci.

    (1993)
  • H. canton et al.

    Eur. J. Pharmacol.

    (1990)
  • H. Fink et al.

    Pharmacol. Biochem. Behav.

    (1984)
  • T. Mita et al.

    Biol. Psychiat.

    (1986)
  • A. Dray et al.

    Brain Res.

    (1978)
  • P. Bobillier et al.

    Brain Res.

    (1976)
  • A. Dray et al.

    Brain Res.

    (1976)
  • H.C. Fibiger et al.

    Neuroscience

    (1977)
  • A. Parent et al.

    Neuroscience

    (1981)
  • C.T. Giambalvo et al.

    Brain Res.

    (1978)
  • A. Pazos et al.

    Brain Res.

    (1985)
  • R.L. Gellman et al.

    Brain Res.

    (1993)
  • A. Pazos et al.

    Neurosci.

    (1987)
  • C.J. Schmidt et al.

    Biochem. Pharmacol.

    (1987)
  • C.E. Connor et al.

    Biochem. Pharmacol.

    (1986)
  • D.M. Stone et al.

    Eur. J. Pharmacol.

    (1986)
  • C.J. Schmidt et al.

    Eur. J. Pharmacol.

    (1986)
  • M.S. Kleven et al.

    Brain Res.

    (1989)
  • C.J. Schmidt et al.

    Eur. J. Pharmacol.

    (1990)
  • C.J. Schmidt et al.

    Eur. J. Pharmacol.

    (1992)
  • C.J. Schmidt et al.

    Eur. J. Pharmacol.

    (1992)
  • C.J. Schmidt et al.

    Eur. J. Pharmacol.

    (1995)
  • D.R. Weinberger

    Trends Neurosci.

    (1988)
  • A.P. Leccese et al.

    Neuropharmacol.

    (1987)
  • A.Y. Deutch et al.

    Brain Res.

    (1990)
  • D.L. Rosin et al.

    Neurosci.

    (1992)
  • F.J. White et al.

    Neuropharmacol.

    (1986)
  • N.R. Swerdlow et al.

    Biol. Psychiatry

    (1986)
  • H. Fink et al.

    Pharmacol. Biochem. Behav.

    (1984)
  • T. Mita et al.

    Biol. Psychiat.

    (1986)
  • D.W. Wooley

    The Biochemical Basis of Psychosis

    (1962)
  • A. Carlsson

    Neuropharmacol.

    (1988)
  • J.H. Gaddum et al.

    Br. J. Pharmacol.

    (1957)
  • J.E. Leyson et al.

    Mole. Pharmacol.

    (1991)
  • H.Y. Meltzer et al.

    J.Pharmacol. Exp. Ther.

    (1989)
  • H.Y. Meltzer et al.

    Pharmacol. Rev.

    (1991)
  • H.Y. Meltzer

    Psychopharmacol.

    (1989)
  • J.P. Bennett et al.

    Arch. Gen. Psychiat.

    (1979)
  • A. Bleich et al.

    Schizo. Bull.

    (1988)
  • H. Imai et al.

    J. Comp. Neurol.

    (1986)
  • S.J. Peroutka et al.

    Mol. Pharmacol.

    (1978)
  • G.P. Reynolds et al.

    J. Neural Transm. [Suppl.]

    (1983)
  • C.J. Schmidt

    Amphetamine and its Analogs

  • J.W. Gibb et al.

    The Neuropharmacology of Serotonin

  • C.J. Schmidt

    J. Pharmacol. Exp. Ther.

    (1987)
  • C.J. Schmidt et al.

    The Neuropharmacology of Serotonin

  • G. Battaglia et al.

    J. Pharmacol. Exp. Ther.

    (1987)
  • D.M. Stone et al.

    J. Pharmacol. Exp. Ther.

    (1988)
  • C.J. Schmidt et al.

    J. Pharmacol. Exp. Ther.

    (1990)
  • C.J. Schmidt et al.

    J. Pharmacol. Exp. Ther.

    (1991)
  • Cited by (214)

    • A novel dual three and five-component reactions between dimedone, aryl aldehydes, and 1-naphthylamine: synthesis and computational studies

      2022, Journal of Molecular Structure
      Citation Excerpt :

      If these ligands act as agonists of 5-HT2C, effects such as appetite suppression and obesity control [75], antipsychotic and antischizophrenic activity [76–78], anti-seizure effects [79], as well as antidepressant properties [80] can be predicted. If these ligands act as antagonists 5-HT2A, effects such as improving ischemic diseases associated with thrombosis [81], improving vascular function in peripheral vascular diseases [82], anti-psychosis [72,83–85], treatment of alcohol and cocaine dependence [85], improving sleep and mood [86], and enhancing the effect of SSRIs in resistant depression are predicted. If these ligands act as antagonists of 5-HT2C, effects such as increased appetite and weight [87,88], treatment of major depressive disorder [89], and anxiolytic effects [90] can be predicted.

    View all citing articles on Scopus
    View full text